I 

115TH CONGRESS 

1ST SESSION H. R. 1660 

To direct the Administrator of the United States Agency for International 

Development to submit to Congress a report on the development and 

use of global health innovations in the programs, projects, and activities 

of the Agency. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 21, 2017 

Mr. SIRES (for himself, Mr. DIAZ-BALART, Mr. CONNOLLY, Mr. ENGEL, Mr. 

SHERMAN, Mr. CICILLINE, Mr. KEATING, Ms. ROS-LEHTINEN, Mr. 

DONOVAN, and Mr. SMITH of New Jersey) introduced the following bill; 

which was referred to the Committee on Foreign Affairs 

A BILL 

To direct the Administrator of the United States Agency 

for International Development to submit to Congress a 

report on the development and use of global health innovations in the programs, projects, and activities of the 

Agency. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Global Health Innova5 tion Act of 2017’’. 


lotter on DSK5VPTVN1PROD with BILLS
2 

•HR 1660 IH

1 SEC. 2. ANNUAL REPORT. 

2 (a) IN GENERAL.—Not later than 180 days after the 

3 date of the enactment of this Act, and annually thereafter 

4 for a period of 4 years, the Administrator of the United 

5 States Agency for International Development shall submit 

6 to Congress a report on the development and use of global 

7 health innovations in the programs, projects, and activities 

8 of the Agency. 

9 (b) MATTERS TO BE INCLUDED.—The report re10 quired by subsection (a) shall include the following: 

11 (1) A description of— 

12 (A) the extent to which global health inno13 vations described in subsection (a) include 

14 drugs, diagnostics, devices, vaccines, electronic 

15 and mobile health technologies, and related be16 havior change and service delivery innovations; 

17 (B) how innovation has advanced the 

18 Agency’s commitments to achieving an HIV/ 

19 AIDS-free generation, ending preventable child 

20 and maternal deaths, and protecting commu21 nities from infectious diseases, as well as 

22 furthered by the Global Health Strategic 

23 Framework; 

24 (C) how goals are set for health product 

25 development in relation to the Agency’s healthVerDate Sep 11 2014 04:20 Mar 23, 2017 Jkt 069200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H1660.IH H1660

lotter on DSK5VPTVN1PROD with BILLS
3 

•HR 1660 IH

1 related goals and how progress and impact are 

2 measured towards those goals; 

3 (D) how the Agency’s investments in inno4 vation relate to its stated goals; and 

5 (E) progress made towards health product 

6 development goals. 

7 (2) How the Agency, both independently and 

8 with partners, donors, and public-private partner9 ships, is— 

10 (A) leveraging United States investments 

11 to achieve greater impact in health innovation; 

12 (B) engaging in activities to develop, ad13 vance, and introduce affordable, available, and 

14 appropriate global health products; and 

15 (C) scaling up appropriate health innova16 tions in the development pipeline. 

17 (3) A description of collaboration and coordina18 tion with other Federal departments and agencies, 

19 including the Centers for Disease Control and Pre20 vention, in support of global health product develop21 ment, including a description of how the Agency is 

22 working to ensure critical gaps in product develop23 ment for global health are being filled. 

24 (4) A description of how the Agency is coordi25 nating and aligning global health innovation activiVerDate Sep 11 2014 04:20 Mar 23, 2017 Jkt 069200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H1660.IH H1660

lotter on DSK5VPTVN1PROD with BILLS
4 

•HR 1660 IH

1 ties between the Global Development Lab, the Cen2 ter for Accelerating Innovation and Impact, and the 

3 Bureau for Global Health. 

Æ 


lotter on DSK5VPTVN1PROD with BILLS